Vertex Announces Phase 2 Results of Combination Treatment in People with One Copy of the F508del CF Mutation

Vertex Pharmaceuticals Inc. announced results from a Phase 2 clinical trial of the cystic fibrosis drug ivacaftor (Kalydeco™) in combination with another potential therapy, lumacaftor, in people with one copy of the F508del mutation, ages 18 and older. In the … Continued

Positive results from Vertex F508del Phase 3 Study with Lumacaftor in Combination with Ivacaftor

Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation Combination of lumacaftor and ivacaftor … Continued

Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels

BACKGROUND: The most common cystic fibrosis-associated mutation, the deletion of phenylalanine 508 (F508del), results in channels with poor membrane expression and impaired function. VX-770, a clinically approved drug for treatment of CF patients carrying the G551D mutation, and VX-809, a … Continued

Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis

Enrollment complete for TRAFFIC and TRANSPORT Phase 3 studies of lumacaftor (VX-809) in combination with ivacaftor for people with two copies of the F508del mutation (homozygous); data expected in mid-2014 12-week Phase 2 study of VX-661 in combination with ivacaftor … Continued

Vertex Present df508 Data at European Cystic Fibrosis Society Conference

Vertex presented data in two talks at the European Cystic Fibrosis Society Conference last week. “VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis.” and … Continued